LLY · Full Picture

ELI LILLY & Co — the full picture

Earnings window · 2026-04-30 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 95
    +35.7% revenue (realized); 3 sources (news, press_release, sec_filing); 1 forward row(s); structured_verified
    Eli Lilly just grew revenue 55.5% in a single quarter while raising full-year guidance to $82 billion to $85 billion.
  2. Product Revenue - Mounjaro and Zepbound · UnclassifiedPriority 94
    +83.2% revenue (realized); 3 sources (news, press_release, sec_filing); 2 forward row(s); structured_verified
    Mounjaro Q1 2026 revenue increased 125% to $8,662 million worldwide
  3. Guidance and Outlook · Guidance & outlookPriority 92
    +8.6% revenue; 3 sources (news, press_release, sec_filing); 4 forward row(s); quote_verified
    Eli Lilly raised its annual profit forecast (annual profit forecast raised).
  4. Market Demand - Anti-Obesity · Demand, orders & backlogPriority 90
    +24.1% revenue (realized); 3 sources (news, press_release, sec_filing); 2 forward row(s); quote_verified
    The global GLP-1 drug market is projected to exceed US$150-200 billion by the early 2030s.
  5. Geographic revenue shift - China NRDL · Geographic mixPriority 89
    +37.4% revenue (realized); 3 sources (news, press_release, sec_filing); quote_verified
    The lower realized prices outside the U.S. were driven primarily by the addition of Mounjaro to the National Reimbursed Drug List (NRDL) in China
  6. Acquired IPR&D Charges · M&A and divestituresPriority 86
    -19.2% operating_income (realized); 3 sources (news, press_release, sec_filing); structured_verified
    Q1 2026 acquired IPR&D charges included in EPS amounted to $0.52 per share compared to $1.72 in Q1 2025
  7. Acquisition Activity and IPR&D · M&A and divestituresPriority 85
    -3.0% cash; 3 sources (news, press_release, sec_filing); 9 forward row(s); structured_verified
    Eli Lilly announced plans to acquire three vaccine developers: Curevo, LimmaTech Biologics, and Vaccine Company in deals potentially totaling up to $4 billion.
  8. 2026 Financial Guidance Update · Guidance & outlookPriority 83
    +10.7% revenue; 3 forward row(s); quote_verified
    Increased 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion
  9. Operating Expense Trends · Operating expenses (SG&A)Priority 80
    -13.4% operating_income (realized); 2 sources (press_release, sec_filing); quote_verified
    Research and development expenses increased 28% to $3.5 billion in Q1 2026 and were 18% of revenue
  10. Business Development / Acquisitions · M&A and divestituresPriority 78
    -1.0% cash; 2 sources (press_release, sec_filing); 5 forward row(s); structured_verified
    Paid $13.3 billion in 2026 related to business development activity, primarily driven by acquisitions of Centessa, Kelonia, Orna, Ventyx, and Ajax.
  11. Net Income and EPS Performance · Operating income & profitabilityPriority 76
    +26.4% operating_income (realized); quote_verified
    Q1 2026 net income was $7.4 billion and EPS was $8.26 compared with net income of $2.8 billion and EPS of $3.06 in Q1 2025
  12. Geographic Market Commentary - China & International · Geographic mixPriority 75
    3 sources (news, press_release, sec_filing); 1 forward row(s); quote_verified
    Revenue outside the U.S. increased 81% to $7.7 billion in Q1 2026

Threads by pillar

Revenue & Demand Priority 99 · 16 threads

Costs & Margins Priority 92 · 11 threads

Capital & Balance Sheet Priority 91 · 8 threads

Strategy & Portfolio Priority 97 · 15 threads

Legal, Regulatory & Policy Priority 89 · 14 threads

Guidance & Outlook Priority 94 · 3 threads

Macro & Market Conditions Priority 86 · 8 threads

Shareholders & Street Priority 61 · 5 threads

Unclassified Priority 100 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
revenue+74.8%+74.8%+180.4%
cash-18.9%+18.9%-6.7%
assets+16.4%+16.4%+1.1%
liability-15.5%+15.5%-16.4%
operating_income-8.2%+8.2%-5.0%
margin+1.7%+1.7%-0.6%
net_income——+47.1%